A Phase I Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Potential Anti-cancer Activity of the AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2015
At a glance
- Drugs GSK 690693 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 18 Dec 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 May 2008 New trial record.